SCHEMBL16749142

SCHEMBL16749142

CC1(C)CC(c2ccc(-c3cccc(C4CC(C)(C)NC(C)(C)C4)c3)cc2)CC(C)(C)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.38
FPR2 P25090 2/20 0.35
NMT1 P30419 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HTR2C P28335 4/20 0.33
KCNH2 Q12809 1/20 0.33
NOTUM Q6P988 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
RAD52 P43351 1/20 0.33
GFER P55789 1/20 0.33
BRD4 O60885 1/20 0.33
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16749058 0.86 KDM1A (0.46) KDM1AKMT2AMEN1L3MBTL1HTR2C
SCHEMBL16749047 0.86 KDM1A (0.39) KDM1AKMT2AMEN1L3MBTL1KCNH2
SCHEMBL16749135 0.84 KCNH2 (0.40) KDM1AKCNH2
SCHEMBL16749046 0.80 KDM1A (0.42) KDM1AKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL16749045 0.80 L3MBTL1 (0.34) KDM1AL3MBTL1ALDH1A1MAPT
SCHEMBL7634175 0.79 KDM1A (0.54) KDM1AKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL16749144 0.77 ALDH1A1 (0.38) KDM1AKMT2AMEN1L3MBTL1KCNH2
SCHEMBL16749052 0.75 KCNH2 (0.38) KDM1AKMT2AMEN1L3MBTL1KCNH2
SCHEMBL20126330 0.75 ALDH1A1 (0.44) KDM1AKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL18351246 0.75 L3MBTL1 (0.33) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160289189-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC CORPORATION (JP) 2016-10-06 US disclosed
US-20160289189-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC CORPORATION (JP) 2016-10-06 US disclosed
EP-3072885-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2016-09-28 EP disclosed
WO-2015076077-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC株式会社 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289189-A1 PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT PLD1, DRD1, CCND1 KDM1A 635/4885FPR2 758/4885NMT1 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.